Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA’s Combination Product Review Process: How It Looks Inside The Agency

This article was originally published in RPM Report

Executive Summary

Biopharma sponsors have precious little to complain about in the current new drug review process, but one area of concern has been uncertainty around combination product reviews. Once limited to diabetes and pulmonary drugs, device-related consults are much more common. FDA conducted its own internal review of the issues – and the findings suggest that the perceptions of sponsors are not far from those of FDA managers. The agency says it is making progress already on improving lines of communications. Here is the report.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS079785

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel